CHINA BIOMEDICAL FUND PHASE I
China Biomedical Fund Phase I (general partnership) was established on November 28, 2014, registered in the British Virgin Islands and is the executive partner of China Biomedical Fund Phase I (Limited Partnership), which is numbered 1851612.
CHINA BIOMEDICAL FUND PHASE I
Founded:
2014-01-01
Status:
Active
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-02-21 | Sumgen Biotech | China Biomedical Fund Phase I investment in Series A - Sumgen Biotech | N/A |
More informations about "China Biomedical Fund Phase I"
China Biomedical Fund Phase I - Crunchbase
Feb 21, 2019 China Biomedical Fund Phase I (general partnership) was established on November 28, 2014, registered in the British Virgin Islands and is the executive partner of China Biomedical Fund Phase I (Limited Partnership), which is numbered 1851612.See details»
China Biomedical Fund Phase I - Crunchbase
Feb 21, 2019 China Biomedical Fund Phase I has invested in Sumgen Biotech on Feb 21, 2019.See details»
China Biomedical Fund Phase I - Crunchbase
Companies like China Biomedical Fund Phase I include Cintrifuse Syndicate Fund, Asia United Fund, and Beida Biomedical Industry Fund.See details»
China Biomedical Fund Phase I - Unicorn Nest
China Biomedical Fund Phase I appeared to be the VC, which was created in 2014.The fund is constantly included in less than 2 deals per year.See details»
Vision 2028: How China could impact the global biopharma industry
Vision 2028: How China could impact the global biopharma industry Biopharmas originating in China will likely have greater influence on the industry by 2028, but regulatory developments …See details»
Investors | GIBF
As one of the largest and most prosperous cities in China, Guangzhou has an advanced healthcare system supported by a great number of comprehensive universities and triple A …See details»
Contract Research Organizations (CROs) in China: integrating …
Nov 19, 2014 The significance of R&D capabilities of China has become increasingly important as an emerging force in the context of globalization of pharmaceutical research and …See details»
Competing in China’s Booming Biopharma Market | BCG
Nov 12, 2020 Multinational companies need to map a strategy to tap into China’s growth—and compete with increasingly innovative “homegrown” Chinese biopharma companies.See details»
Analysis of factors influencing the organizational capacity of ...
Sep 26, 2023 Background Institutional Review Boards (IRBs) play a vital role in safeguarding the rights and interests of both research participants and researchers. However, China initiated …See details»
The dawn of China biopharma innovation - McKinsey & Company
Oct 29, 2021 China’s biopharmaceutical ecosystem is experiencing a momentous shift from a formerly generics-focused play into one that nurtures innovation, with profound implications for …See details»
China at the threshold | Nature Biotechnology
Jul 8, 2021 China is also slashing the prices of generics so it can encourage the sector to fund more innovative medicines. It is investing in biotech, as a limited partner in investment firms or …See details»
China Biomedical Fund Phase I - Crunchbase
China Biomedical Fund Phase I is an investment Fund.See details»
Frontiers | Current situation and future development of the ...
Aug 21, 2022 Introduction: The biomedical industry has grown significantly both globally and in China; however, there are still challenges. This study aimed at evaluating the …See details»
Building an innovation system of medical devices in China: Drivers ...
Jul 20, 2020 This article aimed to discuss the emergence of medical device sector in China from a sectoral innovation system perspective, to explore the drivers and barriers to the successful …See details»
Shanghai Sets Up USD7.6 Billion Fund to Put City at Forefront of ...
Dec 17, 2020 The fund also signed agreements with Shanghai Jiao Tong University’s School of Medicine, Fudan University’s Human Phenome Institute and US medical device firm …See details»
Guangzhou Sino-Israel Biotech Investment Fund (GIBF)
May 10, 2021 GIBF is a Sino-Israeli investment fund established in 2016 and currently invests out of its second fund of $300m. With a ticket size of $5-20m, we are looking to invest in …See details»
Investment benchmark for Asia s biotechnology sector: CES HK ...
The launch of CES HK Biotech will further increase the diversity of the Hong Kong capital market. The use of biotechnology by index constituent stocks in therapies for human illnesses …See details»
Novamab, the world's first inhaled nanobodycompany, officially ...
Among them, LQ036, the world's first inhaled nanobody for asthma, has completed phase I trials in China and Australia, and is currently under phase II investigation in China. Phase I trials …See details»
Sumgen Biotech - Funding, Financials, Valuation & Investors
Sumgen Biotech is funded by 14 investors. Hankang Capital and China Biotech are the most recent investors.See details»
CICC Has Second Close of Biomedical Fund at $648 Million
Jan 14, 2021 CICC Capital announced its RMB biomedical private equity fund, called CICC Qide, has raised $648 million as of the second closing. In February of 2020, CICC announced …See details»